Highest-materiality recent filing
Nu Skin shareholders approve amended 2024 omnibus incentive plan with 2.85M share increase
Shareholders approved Amended and Restated 2024 Omnibus Incentive Plan, increasing share reserve by 2,850,000 to 4,859,919 shares.
Nu Skin EVP & Chief Product Officer Hatchett resigns effective May 8
Steven K. Hatchett resigns as EVP and Chief Product Officer due to family health circumstances.
Nu Skin Q1 revenue $320.6M (-12% YoY), EPS $0.04; guides FY rev $1.35-1.50B
Q1 revenue $320.6M, -12% YoY (1.1% FX tailwind); GAAP EPS $0.04, adjusted EPS $0.14 vs $0.23 prior.
Nu Skin closes $175M term loan and $75M revolver in credit refinancing
$175M term loan fully drawn to repay existing credit agreement; $75M revolving facility also available.
Nu Skin CFO James Thomas resigns; Chelsea Lantz named Interim CFO
James Thomas resigned as EVP and CFO effective March 17, 2026, to pursue an outside opportunity.
Nu Skin appoints Chayce Clark as COO; retains CLO role
Clark appointed EVP, COO & CLO effective March 5, 2026; will oversee global ops, sales, product innovation, tech, brand, and legal.
Nu Skin Q4 revenue $370.3M (-16.9% YoY); FY2025 EPS $3.18, adj. $1.27; Q1 2026 outlook weak
Q4 2025 revenue $370.3M, down 16.9% YoY; EPS $0.29 vs $(0.73) prior year.
Nu Skin Q3 revenue $364.2M (-15.3% YoY); EPS $0.34 in line with guidance
Revenue $364.2M, down 15.3% YoY (down 11.5% ex-Mavely); EPS $0.34 vs $0.17 prior year.
Nu Skin Q2 EPS $0.43 beats guidance; raises FY EPS outlook to $3.05-$3.25
Revenue $386.1M, down 12% YoY; EPS $0.43 (adj. $0.21) vs ($2.38) prior year.
Stockholders approved Amended and Restated 2024 Omnibus Incentive Plan, increasing share authorization by 790,000 shares (30,535,949 for, 1,899,631 against).
Nu Skin Q1 revenue $364.5M at high end of guidance; adj EPS $0.23 excl. Mavely gain
Q1 revenue $364.5M (-12.7% YoY, ~3% FX headwind); GAAP EPS $2.14 includes $176.2M Mavely gain; adjusted EPS $0.23.
Nu Skin director Zheqing (Simon) Shen will not stand for re-election at 2025 annual meeting
Shen informed the company on March 5, 2025, of his decision due to other professional commitments.
Nu Skin Q4 revenue $445.6M, beat guidance; full-year 2025 revenue outlook $1.48-1.62B
Q4 GAAP EPS $(0.73); adjusted EPS $0.38 vs $0.37 prior year; revenue down 8.8% YoY.
Nu Skin Q4 prelim revenue at high end of guidance; closed Mavely deal for $250M
Q4 2024 preliminary revenue at high end of company's guidance range.
Nu Skin sells Mavely to Later for $250M; expects ~$207M cash, $10M stock after distributions
Total consideration $230M cash plus $20M in Purchaser common stock; closed January 2, 2025.
Nu Skin Q3 revenue $430.1M (-13.8% YoY), EPS $0.17; guides lower Q4/FY
Q3 revenue $430.1M (-13.8% YoY); customers 831,768 (-15%), paid affiliates 149,264 (-20%).
Nu Skin adopts amended bylaws updating stockholder proposal and nomination procedures
Board approved Sixth Amended and Restated Bylaws effective Oct 31, 2024.
Nu Skin appoints Mark A. Zorko to board; Audit and Nominating committees
Mark A. Zorko appointed as director effective September 10, 2024, increasing board to nine members.
Revenue $439.1M, down 12.2% YoY; FX headwind of 4.2% ($21.0M).
Nu Skin stockholders approve 2024 Omnibus Incentive Plan, elect directors
Stockholders approved the 2024 Omnibus Incentive Plan, authorizing 1,219,919 new shares plus prior plan carryover.
Nu Skin Q1 revenue $417.3M, down 13%; EPS $(0.01) GAAP; customer base shrinks 19%
Revenue $417.3M, down 13.3% YoY; foreign currency hit of $18.2M; Rhyz revenue up 57.5% to $62.5M.
Andrew Lipman informed Nu Skin on March 15, 2024 of his decision to retire from the Board.
Nu Skin Q4 rev $488.6M (-6%), adj EPS $0.37; CSO departs; FY guide $1.73-1.87B
Q4 revenue $488.6M (-6% YoY), adj EPS $0.37 vs $0.89; reported EPS $0.15.
Nu Skin adopts amended bylaws aligning with Delaware law and updating stockholder meeting procedures
Bylaws amended to align with current DGCL provisions and certificate of incorporation.
Steven K. Hatchett notified the Company that, due to family health circumstances, he determined to resign from his position as Executive Vice President and Chief Product Officer, effective as of May 8, 2026.
On March 5, 2025, Zheqing (Simon) Shen informed Nu Skin Enterprises, Inc. (the “Company”) that he has decided not to stand for re-election to the Company’s Board of Directors (the “Board”) at the Company’s 2025 Annual Meeting of Stockholders due to other professional commitments.
On September 10, 2024, the Board of Directors (the “Board”) of Nu Skin Enterprises, Inc. (the “Company”) appointed Mark A. Zorko as a director of the Company
On March 15, 2024, Andrew Lipman informed Nu Skin Enterprises, Inc. (the “Company”) that he has decided to retire from the Company’s Board of Directors (the “Board”) and will not stand for re-election to the Board at the Company’s 2024 Annual Meeting of Stockholders.
Joseph Chang informed Nu Skin Enterprises, Inc. (the “Company”) that he will be stepping down from his role as Chief Scientific Officer as of March 30, 2024.
Max materiality 0.85 · Median 0.60 · Most common event earnings